Share Article
Urenco supports radiopharmaceutical production research for cancer treatment
07 May 2026 Global SustainabilityUrenco has supported an IAEA Coordinated Research Project aimed at promoting the improved production of radiopharmaceuticals used for cancer therapy.
The International Atomic Energy Agency project concerned the production and quality control practices of Actinium 225 (Ac-225).
Ensuring the appropriate production and quality control of Ac-225 radiopharmaceuticals is critically important, as they involve potent alpha emitting isotopes used for targeted cancer therapy.
A technical workshop, held at the Institute of Nuclear Chemistry and Technology in Warsaw, was attended by 22 researchers from 21 countries and a manual to support the effective planning and implementation of training programmes was produced. This was to ensure consistent, high-quality learning experiences for radiochemists and radiopharmacists.
This guidance document was launched to an expert audience at the European Association of Nuclear Medicine Conference that included a talk on the IAEA’s work with alpha-emitting radiopharmaceuticals.
Rob Little, Head of Sustainability at Urenco said:
“This funding is part of Urenco’s social impact programme and demonstrates how nuclear technology can make a difference in medical research. Urenco Isotopes, based in the Netherlands produces a range of stable isotopes for medical, industrial and research purposes. Urenco is proud to have enabled this important research programme that has delivered tangible outcomes and will result in positive health outcomes for many patients.”
Rafael Mariano Grossi, Director General of the IAEA said:
“Expanding the benefit of nuclear science, especially to less advantaged communities, is not only the right thing to do, but it also helps build trust in the nuclear sector. We are delighted Urenco has joined us in advancing the beneficial uses of nuclear science and technology across the world.”
Share Article
About Urenco
Urenco is an international supplier of uranium enrichment services, fuel cycle products and related solutions with sustainability at the core of our business. Operating in a pivotal area of the nuclear fuel supply chain for over 50 years, Urenco understands the importance of energy security and facilitates the reliable delivery of low carbon electricity generation for consumers around the world.
With its head office in London, UK, Urenco’s global presence ensures diversity and security of supply for customers through enrichment facilities in Germany, the Netherlands, the UK and the USA. Through our technology and the expertise of our people, the Urenco Group provides safe, cost effective and reliable services, operating within a framework of high environmental, social and governance standards, complementing international safeguards.
Urenco is making a positive contribution to global climate change goals through our core business and we are committed to achieving net zero carbon emissions by 2040.
We are committed to continued investment in the responsible management of nuclear materials; innovation activities with clear sustainability benefits, such as nuclear medicine, industrial efficiency and research; and nurturing the next generation of scientists and engineers.
Media enquiries